Hello, welcome to the annual meeting of shareholders of Filana Therapeutics, Inc. Please note that today's meeting is being recorded. During the meeting, we will have a question and answer session. You can submit questions or comments at any time by clicking on the message icon. During this meeting and the question and answer session afterwards, representatives of Filana Therapeutics may make what are known as forward-looking statements. A forward-looking statement is one that is not a historical fact. Forward-looking statements are not guarantees, they involve risks, uncertainties, and assumptions. Such statements represent current expectations or beliefs concerning future events or future performance. Forward-looking statements are predictions only based upon information currently available to the company. Actual events or results could differ materially from those made in any forward-looking statements due to a number of factors, risks, and uncertainties. You should not place undue reliance on these statements. Please refer to Filana Therapeutics' recent filings with the SEC, including Forms 10-K, for a description of the factors that could cause the events or results to differ materially from those made in forward-looking statements. It is now my pleasure to turn today's meeting over to Dr. Claude Nicaise, Chairman of the Board of Directors. The floor is yours. Thank you, Emily. On behalf of our board, it is a pleasure to welcome you to Filana Therapeutics 2026 Annual Meeting of Stockholders. We are pleased to hold this year's meeting virtually. A virtual meeting allows us to be more inclusive and reach out to as many stockholders as possible. As is the custom, we will conduct the business portion of our meeting first and answer your questions at the end of the meeting. I will be acting as chairman of this meeting. Before we begin, I would like to turn the meeting over to Rick Barry, our director and chief executive officer, for a brief company update. Rick? Thank you, Claude. Good morning, everyone. It's been difficult for us to discuss much of substance with our investors since Filana's IND was placed on full clinical hold by the FDA late last year. We've been working very diligently to generate answers to the concerns raised by the FDA. Our team has performed a large number of preclinical experiments with the aim of generating the appropriate data that would answer FDA's questions. We've been scientifically thorough and rigorous as we've endeavored to generate the information FDA needs. We're aiming to provide you with an update on the status of our clinical hold in the coming months. There are several things you should know. One, we've built an organization that's ready to move forward with our TSC-related epilepsy program. As you already should know, Dr. Angélique Bordey, one of the world's recognized experts in TSC, joined us last year as our Senior Vice President of Neuroscience. Dr. Joseph Hulihan joined us as well last year as Chief Medical Officer. Joe is a neurologist and epileptologist who has run a large phase III program in TSC-related epilepsy with Marinus Pharmaceuticals. Clinical group led by Dr. Jack Moore is ready to get started. Two, we've worked very closely with the TSC Alliance, who has been a wonderful partner. Through the alliance, we've met with leading clinicians and clinical trial sites for this indication. Interest in participating in our proof of concept study remains high. Once we are successful in providing FDA with enough information for them to remove the clinical hold, we will have a lot to share about our trial. Three, we have continued to engage with experts in the scientific community. We've received valuable input about how to interpret the results we hope to achieve in our proof of concept study. Four, we know, as Tom Petty sang, that the waiting is the hardest part. I just want you to understand that we're being very careful and deliberate in generating the data that FDA requested. It's been time-consuming, and the delay has been frustrating. We know that TSC patients and their families need new treatment options to deal with this disease. Our two published and successful animal models in this indication give us confidence to move forward with our clinical trial. We're here to make a difference, and we believe we will. Now I'll turn the floor back to our Chairman, Dr. Nicaise. Thanks, Rick. This meeting is now called to order. I have asked Chris Cook, our Chief Operating and Legal Officer, to act as the secretary of this meeting and record the minutes of the meeting. Before proceeding to the formal business, let me introduce you the members of our board of directors who are with us today. Dawn Carter Bir, Bob Anderson, and Rick Barry, our CEO. I would like also to introduce you to the corporate officers who are in attendance. Mr. Barry, Mr. Cook, and Eric J. Schoen, our Chief Financial Officer. Also in attendance today via telephone is Troy Manchac and Judy Foster, representing Ernst & Young LLP. EY is our independent registered public accounting firm. EY will be available to answer questions concerning Filana Therapeutics' financial statements during the question and answer period at the end of the meeting. I have proof of affidavit signed by William Valentin, an employee of Computershare Communication Services, that notice of this meeting has been duly given and that a proxy statement has been furnished to stockholders of record commencing on April 28th, 2026. As stated in the notice, the record date for this meeting was April 21, 2026. As a result, only stockholders of record as of the close of business on that date or person holding a proxy for such stockholder may vote on matters presented at this meeting. I now appoint Chris Cook as Inspector of Election for this meeting. The oath of the Inspector of Election will be filed with the minutes of the meeting. Inspector of Election has been advised that we have present in person or by proxy a sufficient number of shares to constitute a quorum. The meeting is duly constituted and is now called to order. After the formal meeting has been adjourned, we will provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. We also invited stockholders to submit their question via email in advance of the meeting. Out of consideration for others, please limit yourself to one question. Also, no one attending via the webcast is permitted to use any audio recording device. It is now 8:38 A.M. on June 11, 2026, and the polls for each matter to be voted on at this meeting are currently open. Any stockholder who has not yet voted or wish to change their vote may do so by clicking on the voting button on the webcast portal and following the instruction there. Stockholders who have sent in proxies or voted via telephone or Internet and do not want to change their vote do not need to take any further actions. We will vote electronically on the agenda item, and the vote cast today will then be tabulated. The Inspector of Election will make the final tally and report the preliminary result of the vote to you at the end of the meeting. First item of business is the nomination and reelection of three Class II directors. The directors reelected today will hold office for up to the ensuing three years. Richard J. Barry, Pierre Gravier, and Claude Nicaise have been nominated to serve as Class II directors in accordance with corporate bylaws and as described in the proxy statement distributed by stockholders. If you have not previously tendered a proxy, please vote by clicking on the voting button on the web portal and the following instructions. The second item of business is set forth in the proxy is the approval of amendment number 2 to the company's 2018 Omnibus Incentive Plan, which among other things, increase the authorized number of shares issuable thereunder by 4 million shares from 5 million currently to a total of 9 million authorized shares. If you have not previously tendered a proxy, please vote by clicking on the voting button on the web portal and following the instructions there. The third item of business, as set forth in the proxy statement, is the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2026. If you have not previously tendered a proxy, please vote by clicking on the voting button on the web portal and following the instructions there. The fourth item of business is set forth in the proxy statement is to approve by a non-binding advisory vote the 2025 executive compensation for the company's named executive officer. If you have not previously tendered a proxy, please vote by clicking on the voting button on the web portal and following the instructions there. It is now 8:43 A.M. on June 11, 2026, and the polls for each matter to be voted on at this meeting are now closed. No additional ballot proxies or vote and no change or revocation will be accepted. That concludes the formal business of the annual stockholder meeting. As everyone has had the opportunity to vote, I declare the poll closed. The annual stockholder meeting is adjourned. At this time, I would like Chris Cook, the Inspector of Elections, to report on the preliminary result of the voting. Thank you, Claude. Preliminary results indicate the following. Regarding Proposal One, the reelection of three Class II directors, the nominees received the required number of votes for election. Therefore, Richard J. Barry, Pierre Gravier, Dr. Claude Nicaise are duly reelected as Class II directors. Regarding Proposal Two, the approval of amendment number two to the company's 2018 Omnibus Incentive Plan. Proposal Two did receive the required number of votes, and thus the proposal is approved. For Proposal Three, the ratification of the appointment of Ernst & Young as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2026. The proposal received the required number of votes for ratification. Therefore, Ernst & Young is ratified as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2026. Regarding Proposal Four, proposal received the required number of votes for approval. Therefore, the non-binding advisory vote on 2025 executive compensation for the company's executive officers is approved. That concludes the reporting of the preliminary voting results. The final tabulation results will be announced within four business days. I will now turn it over to Rick for a brief question and answer period. Thank you, Chris. We will take stockholders' questions that are being entered today on the web portal and submitted in advance of the meeting via email. Please note we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed. Okay, I don't see any questions. That concludes the question and answer period, I guess. We will now give the floor to Dr. Nicaise to close the meeting. There being no further business, the 2026 annual meeting of the stockholder is closed. Thank you for attending. Operator, This concludes the meeting. You may now disconnect.